Sarepta Therapeutics has superior product

24/7 Wall St. noted that Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen was superior to competing products. The stock price leaped $7.29 to close at $33.36.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.